Saturday 17 October 2026
Export AHG’s income statement to Excel — free account
Akso Health Group Sponsored ADR
AHG Healthcare Medical Distribution
Akso Health Group Sponsored ADR’s revenue for fiscal 2026 (year ended March 2026) was $13.8 million, down 6.40% from fiscal 2025.
1.35
0.00
0.00%
Follow AHG
| Sep '25 | Sep '24 | Sep '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 1.19 | 0.42 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | 99.09 | (4.16) | |
P/B ratio |
— | — | 4.50 | 0.94 | |
Price to Tangible BV |
— | — | 4.50 | 0.94 | |
EV/Sales |
— | — | 1.75 | 1.66 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (2.83) | (2.72) | |
EV/FCF |
— | — | (2.48) | (2.37) | |
Quick Ratio |
1.41 | 7.50 | 1.30 | 0.00 | |
Current Ratio |
1.53 | 8.19 | 1.46 | — | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 2.18% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.02 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.82 | 0.75 | |
Operating CF/Net income |
0.00 | 0.00 | (0.08) | 0.90 | |
Capex/Depreciation |
(143.47) | (7.70) | — | — | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.08 | 0.53 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Graham Net Nets |
— | — | 0.22 | 1.12 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (17.14%) | (86.11%) | |
Free Cash Flow Yield |
— | — | (59.06%) | (165.48%) | |
Revenue per Share |
— | — | 0.04 | 0.06 | |
Operating CF per Share |
0.00 | 0.00 | 0.01 | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.01 | (0.09) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(174.43) | (4.98) | 0.24 | (1.98) | |
Working Capital |
6.37 | 87.98 | 5.33 | — | |
Capital Expenditures |
(175.67) | (0.13) | — | — | |
Net Current Asset Value |
4.66 | 87.92 | 5.33 | (11.62) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.21 | 9.34 | 12.83 | — | |
Average Assets |
116.48 | 131.81 | 24.70 | 26.07 | |
Average Common Equity |
104.11 | 106.47 | 12.44 | 13.00 |
Columns are period end dates